Literature DB >> 26553074

The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation.

Sofia Järnum1, Robert Bockermann1, Anna Runström1, Lena Winstedt1, Christian Kjellman2.   

Abstract

Ag binding to the BCR is a critical step in B cell development and activation, initiating a cascade of signaling events ultimately leading to proliferation, differentiation, or cell death. A bacterial enzyme, IgG-degrading enzyme of Streptococcus pyogenes (IdeS), was shown to specifically cleave IgG molecules below the hinge region of soluble IgG and when IgG is bound to Ag, resulting in one F(ab')2 molecule and one homodimeric Fc fragment. Whether IdeS could also cleave the IgG molecule when it is present in the BCR attached to the B cell membrane in a complex with CD79a and CD79b is unknown. In this article, we present human in vitro and ex vivo data showing that IdeS cleaves the IgG present in the BCR complex and very efficiently blocks Ag binding to the BCR. As a consequence of IdeS cleaving the BCR, signaling cascades downstream of the BCR are blocked, and memory B cells are temporarily silenced, preventing them from responding to antigenic stimulation and their transition into Ab-producing cells.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26553074      PMCID: PMC4671093          DOI: 10.4049/jimmunol.1501929

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  B cell antigen receptor signaling 101.

Authors:  Joseph M Dal Porto; Stephen B Gauld; Kevin T Merrell; David Mills; Aimee E Pugh-Bernard; John Cambier
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

2.  Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development.

Authors:  A Kerry Dobbs; Tianyu Yang; Dana Farmer; Leo Kager; Ornella Parolini; Mary Ellen Conley
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

Review 3.  Maintenance of serum antibody levels.

Authors:  Rudolf A Manz; Anja E Hauser; Falk Hiepe; Andreas Radbruch
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 4.  Initiation and processing of signals from the B cell antigen receptor.

Authors:  M Reth; J Wienands
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 5.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

6.  Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.

Authors:  Ian R Hardy; Nadia Anceriz; François Rousseau; Matt B Seefeldt; Eric Hatterer; Magali Irla; Vanessa Buatois; Laurence E Chatel; Andrew Getahun; Ashley Fletcher; Laura Cons; Guillemette Pontini; Nicole A Hertzberg; Giovanni Magistrelli; Pauline Malinge; Mia J Smith; Walter Reith; Marie H Kosco-Vilbois; Walter G Ferlin; John C Cambier
Journal:  J Immunol       Date:  2014-01-17       Impact factor: 5.422

7.  A technique for the elution of cell-surface antibody from human brain tissue.

Authors:  D Gilden; M Devlin; Z Wroblewska
Journal:  Ann Neurol       Date:  1978-05       Impact factor: 10.422

8.  Blocking of experimental arthritis by cleavage of IgG antibodies in vivo.

Authors:  Kutty Selva Nandakumar; Björn P Johansson; Lars Björck; Rikard Holmdahl
Journal:  Arthritis Rheum       Date:  2007-10

9.  Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; A S Verkman
Journal:  Mol Pharmacol       Date:  2013-04-09       Impact factor: 4.436

10.  IdeS: a bacterial proteolytic enzyme with therapeutic potential.

Authors:  Björn P Johansson; Oonagh Shannon; Lars Björck
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

View more
  12 in total

1.  Transplantation: IdeS to desensitize organ allograft recipients.

Authors:  Georg A Böhmig; Lionel Rostaing
Journal:  Nat Rev Nephrol       Date:  2017-09-11       Impact factor: 28.314

Review 2.  Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.

Authors:  Edmund Huang; Angela Q Maldonado; Christian Kjellman; Stanley C Jordan
Journal:  Am J Transplant       Date:  2021-09-13       Impact factor: 9.369

Review 3.  More than a Pore: Nonlytic Antimicrobial Functions of Complement and Bacterial Strategies for Evasion.

Authors:  Elisabet Bjanes; Victor Nizet
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-27       Impact factor: 11.056

Review 4.  Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues.

Authors:  Kutty Selva Nandakumar
Journal:  Int J Mol Sci       Date:  2018-02-28       Impact factor: 5.923

5.  Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.

Authors:  Hao-Ching Hsiao; Xuejun Fan; Robert E Jordan; Ningyan Zhang; Zhiqiang An
Journal:  Breast Cancer Res       Date:  2018-06-01       Impact factor: 6.466

6.  Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.

Authors:  Tomas Lorant; Mats Bengtsson; Torsten Eich; Britt-Marie Eriksson; Lena Winstedt; Sofia Järnum; Yvonne Stenberg; Anna-Karin Robertson; Kristina Mosén; Lars Björck; Lars Bäckman; Erik Larsson; Kathryn Wood; Gunnar Tufveson; Christian Kjellman
Journal:  Am J Transplant       Date:  2018-04-17       Impact factor: 8.086

Review 7.  The therapeutic challenge of late antibody-mediated kidney allograft rejection.

Authors:  Georg A Böhmig; Farsad Eskandary; Konstantin Doberer; Philip F Halloran
Journal:  Transpl Int       Date:  2019-05-07       Impact factor: 3.782

8.  Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice.

Authors:  Jiaxin Lin; Louis Boon; Robert Bockermann; Anna-Karin Robertson; Christian Kjellman; Colin C Anderson
Journal:  Am J Transplant       Date:  2020-04-07       Impact factor: 8.086

Review 9.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.

Authors:  Ashley Y Choi; Miriam Manook; Danae Olaso; Brian Ezekian; Jaeberm Park; Kyle Freischlag; Annette Jackson; Stuart Knechtle; Jean Kwun
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

10.  Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model.

Authors:  Miriam Manook; Walter J Flores; Robin Schmitz; Zachary Fitch; Janghoon Yoon; Yeeun Bae; Brian Shaw; Allan Kirk; Melissa Harnois; Sallie Permar; Alton B Farris; Diogo M Magnani; Jean Kwun; Stuart Knechtle
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.